Antibody array data showing activation of kinases in human red blood cells infected with the malaria parasite.
New research into malaria suggests targeting enzymes from the human host, rather than from the pathogen itself, could offer effective treatment for a range of infectious diseases, including COVID-19.
The study, conducted by an international team and led by RMIT University’s Professor Christian Doerig, outlines a strategy that could save years of drug discovery research and millions of dollars in drug development by repurposing existing treatments designed for other diseases such as cancer.
The approach shows so much promise it has received government funding for its potential application in the fight against COVID-19.
The study, published in Nature Communications, demonstrated that the parasites that cause malaria are heavily dependent on enzymes in red blood cells where the parasites hide and proliferate.
It also revealed that drugs developed for cancer, and which inactivate these human enzymes, known as protein kinases, are highly effective in killing the parasite and represent an alternative to drugs that target the parasite itself.
Lead author, RMIT’s Dr Jack Adderley, said the analysis revealed which of the host cell enzymes were activated during infection, revealing novel points of reliance of the parasite on its human host.
“This approach has the potential to considerably reduce the cost and accelerate the deployment of new and urgently needed antimalarials,” he said
“These host enzymes are in many instances the same as those activated in cancer cells, so we can now jump on the back of existing cancer drug discovery and look to repurpose a drug that is already available or close to completion of the drug development process.”
As well as enabling the repurposing of drugs, the approach is likely to reduce the emergence of drug resistance, as the pathogen cannot escape by simply mutating the target of the drug, as is the case for most currently available antimalarials.
Doerig, Associate Dean for the Biomedical Sciences Cluster at RMIT and senior author of the paper, said the findings were exciting, as drug resistance is one of the biggest challenges in modern healthcare, not only in the case of malaria, but with most infectious agents, including a large number of highly pathogenic bacterial species.
“We are at risk of returning to the pre-antibiotic era if we don’t solve this resistance problem, which constitutes a clear and present danger for global public health. We need innovative ways to address this issue,” he said.
“By targeting the host and not the pathogen itself, we remove the possibility for the pathogen to rapidly become resistant by mutating the target of the drug, as the target is made by the human host and not by the pathogen.”
Doerig’s team will now collaborate with the Peter Doherty Institute for Infection and Immunity (Doherty Institute) to investigate potential COVID-19 treatments using this approach, supported by funding from the Victorian Medical Research Acceleration Fund in partnership with the Bio Capital Impact Fund (BCIF).
Co-investigator on the grant, Royal Melbourne Hospital’s Dr Julian Druce, of the Victorian Infectious Diseases Reference Laboratory (VIDRL) at the Doherty Institute, was part of the team that were first to grow and share the virus that causes COVID-19, and said the research was an important contribution to efforts to defeat the pandemic.
Royal Melbourne Hospital’s Professor Peter Revill, Senior Medical Scientist at the Doherty Institute and a leader on Hepatitis B research, said the approach developed by the RMIT team was truly exciting.
“This has proven successful for other human pathogens including malaria and Hepatitis C virus, and there are now very real prospects to use it to discover novel drug targets for Hepatitis B and COVID-19,” he said.
The paper is the outcome of an RMIT-led international collaboration with researchers from Monash University in Melbourne, Dr Danny Wilson (University of Adelaide’s Malaria Biology Laboratory Head, The Hospital Research Foundation Fellow and Burnet Institute), Dr Jean-Philippe Semblat (from French Government agency Inserm, Paris) and Prof Oliver Billker (Umeå University, Sweden and Wellcome Sanger Institute, UK).
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Malaria discovery
- 'Shock after shock': A visit to China's secret biolab in California
A city code enforcement officer says she found samples of at least 20 potentially infectious agents at the lab.
- New approaches in fight against drug-resistant malaria
Malaria is one of the most widespread and deadly infectious diseases worldwide. New compounds are continuously required due to the risk of malaria parasites becoming resistant to the medicines ...
- Scientists discover a simple solution to fight malaria-carrying mosquitoes: ‘Both promising and very exciting’
Scientists at the University of Texas at El Paso discovered that adding soap to certain pesticides made the formulations 10 times stronger, as reported by Phys.org. The study was published in the peer ...
- Oldest mosquito in amber reveals bloodsucking surprise
Researchers found a male mosquito trapped in amber 130 million years ago, the oldest ever discovered. And it could do something no male mosquito alive today can do.
- Discovered in Lebanon, Oldest Mosquito Fossil Comes with a Bloodsucking Surprise
Hundreds of thousands of people worldwide are killed annually by malaria and other diseases spread through the bite of mosquitoes, insects that date back to the age of dinosaurs. All of these bites ...
Go deeper with Google Headlines on:
Malaria discovery
[google_news title=”” keyword=”malaria discovery” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Targeting host enzymes to fight disease
- Pathogen Targeting in Chronic Respiratory Diseases: Prevention, Therapy and Management
The burden of chronic respiratory diseases (CRDs) are continuously rising globally. CRDs, including asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and interstitial pulmonary ...
- Graft versus Host Disease (GvHD) News, Research and Latest Updates
Keep abreast with the latest news related to Graft versus Host Disease (GvHD) there are 83 news items on Graft versus Host Disease (GvHD) that covers updates, breakthroughs and in-depth reports.
- Intracellular Targeting of Acyltransferase Enzymes
S-acylation has also been linked to a range of different diseases and there is growing interest in targeting the “zDHHC” enzymes that mediate S-acylation as a potential novel therapeutic strategy.
- Targeting Interleukin-1 in Heart Disease
Preclinical studies also support a pathogenetic role of IL-1 in myocardial disease resulting from doxorubicin toxicity, radiation injury, or genetic mutations leading to dilated cardiomyopathy. 114 – ...
- Groundbreaking Discovery: Inhibiting Key Enzyme May Halt Parkinson’s Disease Progression
The findings open the door to the development of novel therapeutics targeting the enzyme that may slow or prevent the progression of Parkinson’s disease in people—a major unmet need. “Our lab is ...
Go deeper with Google Headlines on:
Targeting host enzymes to fight disease
[google_news title=”” keyword=”targeting host enzymes to fight disease” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
